
NEONC TECHNOLOGIES HOLDINGS, INC. — Investor Relations & Filings
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company that has developed a proprietary, patented platform technology for transporting therapeutics directly to the brain. Its core innovation is an intranasal drug delivery system designed to overcome the limitations of the Blood-Brain Barrier (BBB), enabling more effective treatment for Central Nervous System (CNS) diseases. The company's primary focus is on developing novel therapies for brain cancers, such as glioblastoma, with pipeline candidates including NEO100 and NEO212. The platform is also designed to facilitate the transport of established and new third-party therapeutics, aiming to improve efficacy for a wide range of brain-related conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-18 | English | |
| 10-Q | 2026-05-15 | English | |
| 8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer) | 2026-04-16 | English | |
| 424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer) | 2026-04-16 | English | |
| S-3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer) | 2026-04-10 | English | |
| 8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer) | 2026-04-10 | English |
Browse filings by year
4 yearsMarket data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ernexa Therapeutics Inc.
Biopharmaceutical company developing cell therapies for can…
|
ERNA | US | Manufacturing |
|
ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orph…
|
ERYP | FR | Manufacturing |
|
Esperion Therapeutics, Inc.
Develops and commercializes oral medicines to reduce cardio…
|
ESPR | US | Manufacturing |
|
ESSA Pharma Inc.
Develops drugs targeting the androgen receptor's N-terminal…
|
EPIX | US | Manufacturing |
|
Essex Bio-Technology Limited
Develops and manufactures biologic drugs using recombinant …
|
1061 | HK | Manufacturing |
|
Estrella Immunopharma, Inc.
Clinical-stage biopharma developing T-cell immunotherapies …
|
ESLA | US | Manufacturing |
|
Eton Pharmaceuticals, Inc.
Pharmaceutical company developing and commercializing treat…
|
ETON | US | Manufacturing |
|
EuBiologics Co., Ltd.
A biopharmaceutical company developing vaccines and offerin…
|
206650 | KR | Manufacturing |
|
Eupraxia Pharmaceuticals Inc.
Clinical-stage biotech developing targeted extended-release…
|
EPRX | CA | Manufacturing |
|
EUPRAXIA PHARMACEUTICALS INC.
Clinical-stage biotech developing locally delivered, extend…
|
EPRX | CA | Manufacturing |
NEONC TECHNOLOGIES HOLDINGS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33805/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33805 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33805 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33805 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33805}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for NEONC TECHNOLOGIES HOLDINGS, INC. (id: 33805)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.